Ektomun offers a new, highly promising treatment modality that would add significant value to global healthcare systems.

SCLC is an aggressive form of cancer accounting for about 25% of lung cancer deaths. Despite chemotherapeutic treatments, median survival after diagnosis is no more than 14-20 (limited disease) or 9-11 months (extended disease). Most patients experience progression or relapse of their disease following initial treatment. 

Melanoma is the most aggressive form of skin cancer affecting some 160,000 patients worldwide per year. Scientifically, the disease is hardly understood and treatment options are still poor.